The British Society for Heart Failure gratefully acknowledges the support provided by the ‘Friends of the Society’:

AstraZeneca
GlaxoSmithKline
Medtronic
Merck Pharmaceuticals
Pfizer
Roche
Servier UK
Takeda

For further information, please contact:

BSH Secretariat
‘Nought’ The Farthings
Marcham
Oxfordshire
OX13 6QD
UK

Telephone: +44 (0)1865 861911
+44 (0)1865 391215

Fax: +44 (0)1865 391836

E-mail: bsh@medical-interaction.com

Website: www.bcs.com/affiliates/bsh.html

Registered office as above
Company number: 3767312
Registered charity number: 1075720
Dear Colleague

The principal focus of this year’s Autumn Meeting ‘Heart failure beyond maximum medical management’ is on how to care for severe heart failure patients for whom medical treatment alone is no longer sufficient. The programme will cover the mechanical and surgical options available for these patients and address important palliative care issues, including why patients need palliative care, effective control of symptoms and quality of life. The second session will discuss advances in our understanding of the cellular changes that take place in the heart as heart failure worsens and how they could be reversed. Finally, the last session will review the latest relevant clinical trial results and new pharmacological therapies.

The meeting will be held on Friday 28 November 2003 at the famous Said Business School, which is located only 50 metres from the Oxford railway station and bus station. The symposium is open to any healthcare professionals involved in the diagnosis or treatment of heart failure or those researching the field. The cost of attending the meeting is £25 for BSH members, £100 for non-members and £150 for industry personnel. The fee includes lunch and refreshments.

To register for the meeting, please fill in and return the attached reply slip to the BSH Secretariat, together with a cheque for the appropriate registration fee. They will then contact you with confirmation of your registration and provide a map showing the location of the venue.

Scientific posters can be submitted to be displayed at the meeting, please contact the BSH Secretariat for more information.

CPD, PGEA and RCN accreditation has been applied for.

We look forward to seeing you in Oxford.

BSH Autumn Invite 2003 FINAL 19/8/03 2:17 pm Page 2

Henry Dargie
BSH Chairman

Stephen Westaby
Programme Director

British Society for Heart Failure Annual Autumn Meeting 2003
Heart failure beyond maximum medical management
Friday 28 November, 09.00–17.15
Programme Directors: Stephen Westaby (Oxford) and Adrian Banning (Oxford)

08.30–09.00  BSH Annual General Meeting
12.45  Left ventricular restoration surgery
Stephanie Westaby (Oxford)

Session 1: Introduction
Co-chairs: Henry Dargie (Glasgow) and Stephen Westaby (London)
09.00  Chairs’ introduction
13.05  Discussion
09.05  What is maximum medical treatment?
Philip Poole-Wilson (London)

13.15  Lunch
09.25  What cardiologists need to know about palliative care
Chris Ward (Dundee)

14.15  Discussion
09.40  Living with terminal heart failure: a Jarvik patient’s perspective
Peter Houghton (Birmingham)

14.35  Mechanical circulatory support: resuscitation or permanent treatment?
OH Frazier (Houston, USA) and Stephen Westaby (Oxford)

09.50  Specialist palliative care in end stage heart failure – when, where, how?
Miriam Johnson (Scarborough)

15.10  Discussion
10.05  Tea/coffee

Session 2: New horizons in heart failure management
Co-chairs: Mario Deng (New York, USA) and Stephen Westaby (Oxford)
10.20  Mechanisms of myocardial recovery
Johannes Müller (Berlin, Germany)

15.45  Discussion
10.40  How stem cells help?
Eric Alton (London)

16.00  Discussion
10.55  Apoptosis: role and regulation
Jagat Narula (Philadelphia, USA)

16.10  Discussion
11.30  Tea/coffee

Session 3: Non-transplant interventions
Co-chairs: OH Frazier (Houston, USA) and Jagat Narula (Philadelphia, USA)
11.25  Discussion
11.45  Cardiac resynchronization
Nicholas Peters (London)

12.45  Left ventricular restoration surgery
Johannes Müller (Berlin, Germany)

16.40  Discussion
12.05  The role of implantable defibrillators
Stuart Cobbie (Glasgow)

17.00  Discussion
12.25  Coronary bypass surgery for hibernating myocardium
John Pepper (London)

17.15  Chairs’ closing remarks